Agilent Technologies (NYSE:A) Price Target Raised to $190.00 at JPMorgan Chase & Co.

Agilent Technologies (NYSE:A) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $180.00 to $190.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 21.06% from the stock’s previous close.

A has been the subject of several other research reports. Sanford C. Bernstein upped their price objective on shares of Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Thursday. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Royal Bank Of Canada increased their price target on shares of Agilent Technologies from $155.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Robert W. Baird lifted their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and an average price target of $165.65.

Agilent Technologies Stock Performance

Shares of A traded up $1.86 during mid-day trading on Thursday, hitting $156.94. 1,643,520 shares of the company’s stock were exchanged, compared to its average volume of 2,230,675. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $163.75. The stock’s 50-day simple moving average is $139.16 and its 200-day simple moving average is $126.65. The firm has a market cap of $44.33 billion, a price-to-earnings ratio of 31.48, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The business had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the prior year, the business posted $1.37 earnings per share. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities research analysts expect that Agilent Technologies will post 6.05 EPS for the current year.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in Agilent Technologies by 12,343.3% in the second quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after purchasing an additional 54,138,451 shares during the last quarter. Norges Bank bought a new stake in shares of Agilent Technologies during the fourth quarter worth about $549,158,000. Bank of New York Mellon Corp increased its stake in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after buying an additional 2,440,360 shares during the period. Legal & General Group Plc acquired a new position in shares of Agilent Technologies in the second quarter valued at approximately $260,101,000. Finally, AQR Capital Management LLC raised its holdings in Agilent Technologies by 424.1% in the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after buying an additional 1,652,244 shares during the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Quarterly results exceeded expectations: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS was $1.62 versus expectations of $1.49, while GAAP net income reached $362 million, or $1.28 per share, compared with $336 million a year earlier. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Improving demand and profitability supported the outlook: Management cited strengthening demand for laboratory tools used in research and drug development. Operating profit increased 23.3% to $444 million, and operating cash flow rose 43.4% to $519 million. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Fiscal-year guidance was raised above consensus: Agilent now expects fiscal 2026 adjusted EPS of $6.18-$6.21, versus the $6.06 analyst consensus, and revenue of approximately $7.5 billion, above the $7.4 billion estimate. Fourth-quarter EPS guidance of $1.71-$1.74 also brackets or exceeds consensus. Agilent Boosts FY View on Higher 3Q Profit, Revenue
• Positive Sentiment: Analysts became more constructive: TD Cowen and Sanford C. Bernstein raised their price targets to $180 and assigned Buy/Outperform ratings. RBC lifted its target to $185 and maintained an Outperform rating, implying roughly 14%-17% upside from recent trading levels. Analyst price-target revisions reported by Benzinga
• Neutral Sentiment: At approximately $157.85, Agilent is trading near its 52-week high, which may limit immediate upside despite the improved fundamental outlook and higher analyst targets.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.